Q2 2026 Microbix Biosystems Inc Earnings Call Transcript
Key Points
- Microbix Biosystems Inc (MBXBF) has successfully built capabilities and capacity, modernizing antigen production and creating quality test control products.
- The company is optimistic about securing unprecedented scale opportunities with prospective customers, indicating potential for significant business growth.
- Microbix Biosystems Inc (MBXBF) maintains a strong balance sheet, with $8.1 million in cash, allowing it to navigate current challenges and invest in future growth.
- The company has achieved credibility through successful audits by major companies, positioning itself as a reliable supply chain partner.
- Microbix Biosystems Inc (MBXBF) is advancing its Kinlytic file towards a supplemental Biologicals Licensing Application, which is expected to be a significant value creator.
- Microbix Biosystems Inc (MBXBF) reported a disappointing Q2 with revenues well below the engineered breaking point of $5.5 million, resulting in a net loss.
- Sales to China have significantly decreased, impacting year-over-year comparability and contributing to the revenue shortfall.
- Margins are lower than targeted due to fixed manufacturing costs being absorbed within lower volumes, leading to higher cost of sales.
- The company is experiencing delays in antigen sales, which were expected to land in Q2 but have been postponed to later in the year.
- There is uncertainty regarding the timing and scale of revenue recovery from the Chinese market, with potential fluctuations in demand.
Good morning, everyone. Thanks for joining us today. We have an update with Microbics who just put out their Q2 numbers this morning. So hopefully everyone's had a chance to review those.
With me on the call, I have. Cameron Groom, CEO, Ken Hughes, COO, Jim McCurry, COO. I'm not sure if we're going to work off a presentation today, but as always, this session will contain forward-looking statements. If you'd like to know more about those, you can find them on the presentation on the company's website.
And there will be a Q&A section, so feel free to enter any questions you have in the Q&A box.
And with that out of the way, I'd like to turn the mic over to Cameron. Hi, Cameron.
Good morning, Deborah. Thank you so much. Good morning, Ken and Jim. I just want to thank everybody on the call for joining us for this update call this morning.
As everybody will have seen from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
